This is a StreetInsider.com Premium Only Page

Exelixis (EXEL) – StreetInsider.com Reports

Apr 11, 2024 04:34 AM Barclays Downgrades Exelixis (EXEL) to Equalweight

Feb 7, 2024 07:07 AM Exelixis (EXEL) PT Raised to $28 at RBC Capital

Feb 6, 2024 04:13 PM Exelixis (EXEL) Tops Q4 EPS by 10c, offers guidance

Feb 2, 2024 07:47 AM Exelixis (EXEL) PT Raised to $25 at Stifel

Jan 30, 2024 04:23 AM Exelixis (EXEL) PT Raised to $25 at Barclays

Jan 25, 2024 08:00 AM Exelixis (EXEL) Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib in Combination with Atezolizumab

Jan 22, 2024 05:01 PM Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial

Jan 18, 2024 04:07 PM Exelixis (EXEL) Reports EU Patent Office Ruled in Favor of Exelixis on Formulation Patent Covering CABOMETYX

Jan 17, 2024 05:55 AM Exelixis (EXEL) PT Raised to $28 at Wells Fargo

Jan 8, 2024 05:25 AM Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance

Dec 26, 2023 09:42 AM Healthcare a contrarian idea into 2024 - these stocks could see upside

Dec 19, 2023 06:42 AM Exelixis (EXEL) PT Raised to $27 at Wells Fargo

Dec 19, 2023 05:07 AM BTIG Starts Exelixis (EXEL) at Buy

Dec 15, 2023 03:17 AM Citi Starts Exelixis (EXEL) at Buy

Dec 4, 2023 08:03 AM Exelixis (EXEL), Arcus Biosciences (RCUS) Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Nov 10, 2023 09:00 AM Exelixis (EXEL) Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Nov 2, 2023 09:18 AM Exelixis (EXEL) PT Raised to $23 at Morgan Stanley

Nov 1, 2023 04:26 PM Exelixis (EXEL) Misses Q3 EPS by 5c

Sep 26, 2023 06:08 AM H.C. Wainwright Starts Exelixis (EXEL) at Buy

Sep 12, 2023 08:03 AM Exelixis (EXEL) and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

Aug 24, 2023 08:00 AM Exelixis (EXEL) Reports Positive Results from Phase 3 CABINET Pivotal Trial of Cabozantinib

Aug 23, 2023 04:30 PM Exelixis (EXEL) Appoints Amy Peterson as Chief Medical Officer

Aug 22, 2023 06:14 AM Exelixis (EXEL) PT Raised to $29 at Oppenheimer

Aug 21, 2023 04:58 PM Exelixis (EXEL) PT Raised to $27 at JMP Securities

Aug 8, 2023 06:05 AM SVB MoffettNathanson Starts Exelixis (EXEL) at Market Perform

Aug 3, 2023 05:01 AM Exelixis (EXEL) PT Lowered to $24 at Barclays

Aug 2, 2023 08:39 AM Exelixis (EXEL) PT Raised to $22 at Morgan Stanley

Aug 2, 2023 08:22 AM Exelixis (EXEL) PT Raised to $23 at Stifel

Aug 1, 2023 04:11 PM Exelixis (EXEL) Tops Q2 EPS by 14c

Jul 11, 2023 02:17 AM Morgan Stanley Resumes Exelixis (EXEL) at Equalweight

May 10, 2023 03:38 AM Piper Sandler Assumes Exelixis (EXEL) at Overweight

May 9, 2023 04:13 PM Exelixis (EXEL) Tops Q1 EPS by 1c

May 8, 2023 05:27 AM Exelixis (EXEL) Announces Departure of Lance Willsey from Board

Apr 18, 2023 09:45 AM Increasing unusual option volume: GMDA EXEL CHGG FRC MCRB RL MAT WAL BIRD

Apr 13, 2023 04:11 PM Exelixis (EXEL) Advances Board Refreshment Plan

Apr 12, 2023 08:49 AM Exelixis (EXEL) PT Lowered to $21 at Morgan Stanley

Apr 5, 2023 08:04 AM Farallon Issues Letter to Exelixis (EXEL) Board of Directors Outlining Case for Change

Mar 20, 2023 07:00 AM Exelixis (EXEL) Announces $550 Million Share Repurchase Program

Mar 9, 2023 07:02 AM Wells Fargo Starts Exelixis (EXEL) at Overweight

Mar 3, 2023 05:50 AM Exelixis (EXEL) Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab

Feb 13, 2023 05:02 PM Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial

Feb 13, 2023 08:02 AM Exelixis (EXEL) and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Feb 9, 2023 08:45 AM Exelixis (EXEL) PT Lowered to $20 at Stifel

Feb 8, 2023 07:49 AM Exelixis (EXEL) PT Lowered to $26 at Jefferies

Feb 8, 2023 06:59 AM Exelixis (EXEL) PT Lowered to $25 at RBC Capital

Feb 7, 2023 04:22 PM Exelixis (EXEL) Tops Q4 EPS by 8c

Jan 26, 2023 04:05 AM Credit Suisse Starts Exelixis (EXEL) at Outperform

Jan 20, 2023 05:52 AM Exelixis (EXEL) Issues Update on Patent Litigation with MSN Laboratories

Jan 19, 2023 02:32 AM Exelixis (EXEL) PT Lowered to $24 at JMP Securities

Jan 11, 2023 07:51 AM Exelixis (EXEL) PT Raised to $27 at Oppenheimer